PharmAbcine

Notifications

Back

Notification settings

Back

Post notifications

Be notified when someone leaves a comment or a reply to your post or comment.

Updates and news

Stay ahead of important updates and news from the site.

Alarm
My account Sign out

Sign-in required.

Executive Committee
Board of Directors
Scientific Advisory Board
History

Core Technology

Fully Human Antibody Library
Antibody Development
Antibody Engineering

Olinvacimab
PMC-309
PMC-402
PMC-403

Recruiting Procedure
Careers Guide
Job Openings

Location
Inquiry
Partnership Request

한국어
English

About Us

Executive Committee
Board of Directors
Scientific Advisory Board
History

Core Technology

Fully Human Antibody Library
Antibody Development
Antibody Engineering

Pipeline

Olinvacimab
PMC-309
PMC-402
PMC-403

For Investors

For Media

Careers

Recruiting Procedure
Careers Guide
Job Openings

Contact

Location
Inquiry
Partnership Request

한국어
English

About Us

Executive Committee
Board of Directors
Scientific Advisory Board
History

Core Technology

Fully Human Antibody Library
Antibody Development
Antibody Engineering

Pipeline

Olinvacimab
PMC-309
PMC-402
PMC-403

For Investors

For Media

Careers

Recruiting Procedure
Careers Guide
Job Openings

Contact

Location
Inquiry
Partnership Request

한국어
English

한국어
English

Core Technology

For Media

News Article PharmAbcine and Arontier Partnership for AI-Driven Antibody-Based Drug Development Platform_THE BIO

TitlePharmAbcine and Arontier Partnership for AI-Driven Antibody-Based Drug Development Platform_THE

12 Feb 2025 Views 845

Press Release PharmAbcine at JP Morgan Healthcare Conference 2025

TitlePharmAbcine at JP Morgan Healthcare Conference 2025Category PharmAbcine at JP Morgan Healthcare

10 Jan 2025 Views 1457

Press Release PharmAbcine Announces Safety Approval for 3mg Multiple-dose Cohort in Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration

Title PharmAbcine Announces Safety Approval for 3mg Multiple-dose Cohort in Phase 1 Clinical Trial o

9 Jan 2025 Views 1287

Press Release PharmAbcine Announces Safety Approval for 4mg Single-dose Cohort in Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration

TitlePharmAbcine Announces Safety Approval for 4mg Single-dose Cohort in Phase 1 Clinical Trial of P

16 Oct 2024 Views 2188

Media Center

Subscribe to our website to get latest updates (email@exmaple.com)

Confirm

No
Category
- Show all
- Press Release
- News Article
- PR Video
- CEO Story
Title
Author
Time uploaded
Views
Likes

192
Press Release
Press Release PharmAbcine Announces First Patient Dosed in Phase 1a/b Clinical Trial of PMC-309 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced or Metastatic Solid Tumors
PharmAbcine
24 Jan 2024
Views2924
0

191
Press Release
Press Release PharmAbcine’s Phase 1 Ophthalmology Program PMC-403 Selected by the KDDF for Government-initiated Drug Development Program
PharmAbcine
6 Dec 2023
Views2854
0

190
Press Release
Press Release PharmAbcine Publishes Study in Science Advances Demonstrating the Potential of PMC-403 in Preclinical Models of Idiopathic Systemic Capillary Leak Syndrome
PharmAbcine
23 Nov 2023
Views2510
0

189
Press Release
Press Release PharmAbcine Receives Safety Review Committee Approval to Advance to Dose Level 2 of Clinical Trial of PMC-403 with Neovascular Age-related Macular Degeneration following Dose Level 1 Safety Data
PharmAbcine
9 Nov 2023
Views2574
0

188
Press Release
Press Release PharmAbcine Receives HREC Approval in Australia for the Phase 1a/b Trial of Its Anti-VISTA Antibody PMC-309 in Combination with KEYTRUDA® (pembrolizumab)
PharmAbcine
18 Sep 2023
Views2613
0

187
Press Release
Press Release PharmAbcine Receives IND Approval from the Korean MFDS for Phase I Clinical Trial of Its Novel TIE2 Agonistic Antibody in nAMD
PharmAbcine
24 May 2023
Views3530
0

186
CEO Story
CEO Story IMAPAC Singapore Biopharma Awards 2023
PharmAbcine
24 Mar 2023
Views2842
0

185
CEO Story
CEO Story Clinical Trials Festival Asia 2023 - IMAPAC
PharmAbcine
20 Jan 2023
Views4593
0

184
CEO Story
CEO Story Dr. Yoo to participate in the 41th Annual J.P. Morgan Healthcare Conference
PharmAbcine
27 Dec 2022
Views3016
0

183
Press Release
Press Release PharmAbcine Announces Collaboration Agreement with MSD to Evaluate Anti-VISTA Antibody PMC-309 in Combination with KEYTRUDA® (pembrolizumab)
PharmAbcine
13 Dec 2022
Views3415
0

Previous
1
2
3
4
5
6
7
8
9
Next

About Us
Core Technology
Pipeline
- Olinvacimab
- PMC-309
- PMC-402
- PMC-403
For Investors
For Media
Careers
Contact

LinkedIn I Facebook I YouTube

- 2F, Research Building 2, 70, Yuseong-daero 1689 beon-gil,
  Yuseong-gu, Daejeon, 34047, Republic of Korea
- HQ +82-42-863-2017
- R&D Center +82-42-861-2017
- FAX +82-42-863-2080
COPYRIGHT BY PharmAbcine Inc. ALL RIGHTS RESERVED.

2F, Research Building 2, 70,

Yuseong-daero 1689 beon-gil,
Yuseong-gu, Daejeon, 34047, Republic of Korea

HQ +82-42-863-2017

R&D Center +82-42-861-2017

Investor Relations +70-4294-6097

FAX +82-42-863-2080

COPYRIGHT BY PharmAbcine Inc.

ALL RIGHTS RESERVE